High Intensity Focused Ultrasound Market

High Intensity Focused Ultrasound Market Analysis and Forecast to 2035: Type, Technology, Component, Application, Device, End-UserHigh Intensity Focused Ultrasound Market is anticipated to expand from $1.3 billion in 2025 to $2.6 billion by 2035, growing at a CAGR of approximately 7.1%. GDP Growth Influence: Rising healthcare spending boosts HIFU adoption. For instance., Japans health spending, projected to exceed 12% of GDP by 2029, supports wider use of non-invasive HIFU therapies.
Investment Scenario: Strategic funding is accelerating HIFU innovation. For example, EDAP secured a 36M credit facility from the European Investment Bank in 2025 to expand Focal One Robotic HIFU capabilities across Europe.
Reimbursement & Policy Impact: Supportive reimbursement policies are driving HIFU adoption by improving affordability and provider incentives. In the U.S., CPT Code 55880 enables Medicare reimbursement for prostate HIFU, with hospitals like Lakewood Ranch Medical Center and providers in the HIFU Prostate Services (HPS) network treating hundreds of Medicare patients. In France, the provisional CCAM code JGND858 (effective September 1, 2025) for transrectal HIFU further promotes clinical uptake for localized prostate treatments.
Geopolitical Stability / Supply Chain Risk: HIFU device manufacturers like EDAP TMS rely on a small number of suppliers for key components such as ultrasound transducers, which interruptions in supply can delay manufacturing and delivery of HIFU systems and increase costs for example, a strategic change by a major ultrasound supplier led to cost increases in EDAPs HIFU systems in 2024.
Commodity & Raw Material Prices: Hospitals integrating HIFU systems must account for rising costs of precision motors and MRI-compatible components. For example, the European Investment Bank reported that EDAP secured a 36million credit facility in part to mitigate high capital costs associated with such advanced materials.
Intellectual Property / Patent Risk: Focal One HIFU devices may face claims of patent infringement by third parties, which could restrict commercialization or delay market adoption, potentially affecting EDAPs company ability to expand HIFU system deployments
Technological Advancement Rate: Innovation is accelerating in robotic and imaging-guided HIFU platforms. For instance, in November 2025, EDAP received FDA 510(k) clearance for the latest evolution of its Focal One Robotic HIFU system, supporting enhanced precision in prostate ablation procedures.

Segment Overview
Based on the type segmentation of the high intensity ultrasound market, the market is segmented intoUltrasound-based HIFU, and MRI-based HIFU.
Industry trends toward noninvasive therapies, precision oncology, and realtime imaging are converging to shape demand across both segments, driving adoption in hospitals, specialized cancer centers, and radiology practices worldwide.
Prostate cancer is the second-leading cause of cancer death among American men, with about 1 in 44 men dying from it (American Cancer Society, 2025), driving strong demand for non-invasive treatment options like HIFU.
In Ultrasound HIFU Therapy, focused ultrasound energy is delivered under direct ultrasound guidance to ablate targeted tissue without surgery. This modality sees widespread clinical use in treating solid tumors for example, HIFU systems such as Ablatherm and Sonablate 500 have been used for prostate cancer ablation with ultrasoundguided focal therapy platforms showing encouraging oncologic and functional outcomes in patient cohorts with localized prostate cancer.
Rising prevalence of uterine fibroids is driving demand for MRI-HIFU Therapy. Globally, uterine fibroids affect 7080% of women by age 50 (The Journal of Contemporary Clinical Practice, 2025),
Similarly, According to the International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS, January 2025, 14(1)), prevalence estimates indicate that uterine fibroids affect 5.4% of women. MRI-guided HIFU has been explored as a non-invasive treatment option, particularly in conjunction with releasing intrauterine systems for targeted therapy.
Advanced MRI-HIFU product launches are set to fuel segment growth. Apollo Hospitals recently launched MRI-HIFU for the treatment of uterine fibroids in India, providing women a non-invasive alternative to surgery with no radiation, no scars, minimal anesthesia, and faster recovery.

Geographical Overview
North America leads the global HIFU market, with the U.S. accounting for the vast majority of procedure volumes across oncology, neurology, and gynecology, largely due to strong healthcare infrastructure and early adoption of non-invasive technologies.
Expanded insurance reimbursement coverage in the U.S. for uterine fibroid HIFU procedures has significantly increased adoption in outpatient centers and specialty clinics in recent years.
The region has seen sustained R&D investment in HIFU clinical trials, including AI-guided sonication and robotics integration, underscoring innovation in precision and safety.
Major academic hospitals and cancer centers actively deploy HIFU for prostate, liver, and neurological indications, supporting clinical evidence and guideline inclusion.
Strategic partnerships between device developers and large imaging/technology firms have accelerated next-generation HIFU solutions tailored for broader therapeutic use.
North Americas competitive landscape is shaped by key players expanding their installed base and service models, including subscription and equipment-as-a-service options to lower capital barriers for clinics.

Asia-Pacific is the fastest-growing HIFU market, with China, Japan, South Korea and Australia leading adoption due to expanding healthcare infrastructure and a growing focus on non-invasive oncology and gynecology treatments.
China has subsidized HIFU for uterine fibroid treatment in many hospitals, helping reduce patient costs and boost procedure volumes at a regional level.
Japans regulatory approvals for neurological HIFU therapies have enabled thousands of treatments, positioning it as a hub for advanced HIFU applications beyond oncology.
South Koreas aesthetic and cosmetic HIFU segment continues to expand rapidly, driven by high consumer demand for non-surgical skin and beauty procedures.
Strategic collaborations between international HIFU device makers and local OEMs have supported device localization and cost reductions, increasing accessibility in secondary cities.
Government healthcare initiatives and rising middle-class demand for high-quality care further accelerate HIFU adoption across hospitals and specialty clinics.

Key Trends and Drivers
Advancements in Real-Time Imaging & Targeting Precision
The HIFU market is rapidly advancing due to improvements in real-time imaging and AI-assisted targeting, which enhance procedural accuracy and efficiency. Focal One robotic HIFU, powered by AI technology like Unfold AI from Avenda Health, accurately predicts tumor boundaries in prostate cancer, minimizing damage to surrounding tissue and improving treatment precision. AI-assisted workflows are also enabling remote and robotic procedures. For example, the Cleveland Clinic successfully performed the worlds first transcontinental robotic-assisted Focal One HIFU procedure for prostate cancer, treating a patient in Abu Dhabi in real time.
Similarly, Cortechs.ai and EDAP conducted the first OnQ Prostate-Assisted Focal One robotic HIFU procedure at UCSF Prostate Cancer Center, demonstrating the technologys potential for high-precision, remotely guided treatment. Sonovein integrates robotics with continuous real-time ultrasound imaging, allowing clinicians to monitor and adjust energy delivery during varicose vein treatment, showcasing AI-driven automation in HIFU applications beyond oncology. These innovations enhance targeting accuracy, shorten planning cycles, and expand HIFU access across oncology and other therapies.

Rising Prevalence of Uterine Fibroids
The market is witnessing rising demand for high-intensity focused ultrasound (HIFU). According to the U.S. National Institutes of Health (NIH), 2025% of women of reproductive age are affected by fibroids, with prevalence increasing sharply with age. By 50 years, up to 80% of Black women and 70% of White women develop fibroids, underscoring a large and persistent patient pool requiring effective treatment options.
Similarly, as per the Center for Uterine Fibroid Uterine fibroids are the most common solid pelvic tumors in women, causing significant symptoms in about 25% of reproductive-age patients, particularly women in their 40s and early 50s, driving strong demand for non-invasive, uterus-preserving treatment options. The substantial surgical burden associated with fibroid management is further driving demand for HIFU. Approximately one-third of all hysterectomies performed in the United States nearly 100,000 procedures annually are attributed to fibroid-related conditions. This high invasive surgery rates are boosting demand for safer, organ-preserving treatments. Additionally, fibroids account for one in five gynecology visits in the U.S., highlighting their significant healthcare utilization and economic burden. Growing awareness of non-surgical options is driving HIFU adoption as a uterus-preserving, outpatient treatment.

RECENT DEVELOPMENTS
In November 2025, FUSMobile, Inc. had announced that it has received De Novo marketing authorization (DEN250015) from the U.S. Food and Drug Administration (FDA), granting clearance to market and distribute the Neurolyser XR system for the non-invasive treatment of low back pain.
In November 2025, Merz Aesthetics announced FDA clearance to expand Ultherapy PRIME for skin laxity treatment on anterior arms, posterior arms, and abdomen with real-time imaging.
In November 2025, U.S. FDA granted 510(k) clearance for the latest enhancements in the Focal One HIFU system, including advanced imaging and workflow improvements, reinforcing EDAP's leadership.
In March 2025, Chongqing Haifu Medical Technology Co., Ltd. successfully conducted a remote HIFU surgery on a 35-year-old fibroid patient in Kenya from Chongqing, China via 5G telemedicine. This milestone was achieved during the 6th Multicenter Womens Health Campaign.
In March 2025, Insightec partnered with the Vattikuti Foundation and AIIMS (India) to expand access to focused ultrasound care and advance neurological research, including donation of the Exablate Neuro system.

KEY PLAYERS
Insightec Ltd., EDAP TMS S.A., Chongqing Haifu Medical Technology Co., Ltd., Philips Healthcare, Sonablate (SonaCare Medical), Theraclion SA, ALPINION Medical Systems, Profound Medical Corp., Ultherapy (Merz Aesthetics), HIFU Prostate Services, Vermon S.A., FUSMobile Inc., ULTRAISER, Lynton Lasers Ltd.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation. Show more